Am ixture of 3-(1H-imidazol-1-yl)-1-phenylpropan-1-one [2] (10 mmol), hydroxylamine hydrochloride (20 mmol), and KOH (20 mmol) in ethanol (10 mL) was heated to reflux under stirring for 18 hrs. The reaction mixture was allowed to cool to room temperature and the insoluble solids were filtered off. Thefiltrate was concentrated under vacuum and the residue was poured onto icecold water (15 mL). The precipitated solid was collected by filtration and dried to give the respective oximen amely, (1E)-Nhydroxy-3-(1H-imidazol-1-yl)-1-phenylpropan-1-imine [3] . A solution of the 4-chlorobenzoic acid (7 mmol) and EDCI HCl (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride,7.3 mmol) was stirred in dichloromethane (75 mL)i nt he presence of DMAP (4-dimethylaminopyridine,400 mg). (1E)-N-Hydroxy-3-(1H-imidazol-1-yl)-1-phenylpropan-1-imine (6.9 mmol) was added to the stirred reaction mixture and stirring was continued for afurther 18 hrs at room temperature. The reaction mixture was washed successively with water (2´20 mL), 10% NaHCO 3 solution (2´15 mL), and water (2´15 mL). Theorganic layer was separated, dried (Na 2 SO 4 )a nd evaporated underr educedpressureand theresidue wascrystallized from isopropanol to give colourlessc rystalso ft he titlec ompound( m.p. 399.15-401.15 K[3]) which were suitable for X-ray crystallography.
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Discussion
The incidence of fungal infections, both invasive and superficial, has recently emerged as agrowing threat to humanhealth especially in patients with weakened or compromised immune systems [4, 5] . Azoles areone of themajor classes which are used to treat fungal infections in clinics. The title compound is an imidazole-containing potent anti-Candida agent having am inimuminhibitory concentration (MIC)value of 0.0054 µmol/mL towards clinical isolates of Candida albicans being about 3.5-fold and 300-fold more potent than miconazole( MIC =0 .0188 µmol/mL) and the gold standard azole antifungal, fluconazole (MIC =1.6325 µmol/mL), respectively [3] . The E isomerofthe titlec ompounda sak inetically favored candidate was detected over the Z isomer due to the steric factor. The single bond N3-O1 is clearly characterized by the distance of 1.4354(17) Å. Thedouble bond of C6=N3 is characterized by the distance of 1.2831(19) Å. The molecules packing in the crystal structure is stabilized by one weak intermolecular interaction,o fw hich N2 of the imidazole moiety works as acceptor and C19 works as donor. The distance H19···N2 is 2.527(17) Åand the angle C19-H19···N2 is 141.9(15)°. There is one intramolecular H-bond in the molecule. The distance of the interaction H4B···O1 is 2.539(16) Åand the angle C4-H4B···O1 is 112.6(14)°. 
